Renal Dislipidemi ve Tıbbi Beslenme Tedavisi

Kronik böbrek yetmezliği (KBY) olan hastalarda morbidite ve mortalitenin en önemli nedeni, ateroskleroik kardiyovasküler hastalıklardır. Son dönem böbrek yetmezliğinde hipertrigliseridemi lipit anormallikleri oldukça yaygındır. Bazı lipoprotein fraksiyon bileşim bozuklukları sık olarak görülür. En belirgin olanları çok düşük dansiteli lipoprotein (VLDL) kolesterol, trigliserit, düşük dansiteli lipoprotein (LDL) kolesterol, orta dansiteli lipoprotein (IDL) kolesterol artışı ile yüksek dansiteli lipoprotein (HDL) kolesterolde azalmadır. Bu hastaları kardiyovasküler hastalıklar (KVH)dan korunmak için kan lipit profili düzenlenmeli ve uygun tıbbi beslenme tedavisi uygulanmalıdır

Renal Dyslipidemia and Medical Nutrition Therapy

Arteriosclerotic cardiovascular disease is the most important cause of morbidity and mortality in Chronic Renal Failure (CRF) patients. In End-Stage Renal Failure, hypertriglyceridemic lipid abnormalities are quite common. Some of the lipoprotein disorders are frequently seen as a fraction. Most notable is the increased very low density lipoprotein (VLDL) cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, intermediate-density lipoprotein (IDL) cholesterol and decreased high-density lipoprotein (HDL) cholesterol. In these patients blood lipid profile should be regulated and appropriate medical nutrition therapy should be applied for prevention from cardiovascular diseases.

PDF

___

1. Ikemori A. Urinary fatty acid binding protein in renal disease. Clin Chim Acta 2006;374:17.
2. Güllülü M. Lipitler ve Böbrek. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 2012;I(10):1-6.
3. Chertow GM, Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:12961305.
4. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:15241538.
5. Vaziri ND. Lipotoxicity and impaired HDL mediated reverse cholesterol/lipid transport in chronic kidney disease. J Renal Nutr 2010;20:35S43.
6. Vaziri ND. Dyslipidemia of chronic renal failure: The nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 2006;290:262272.
7. Sarnak M, Levey A, Schoolwerth A, Coresh J, Culleton B, Hamm L, et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 2003;108:21542169.
8. Tsimihodimos V. Dyslipidemia in chronic kidney disease: An approach to pathogenesis and treatment. Am J Nephrol 2008;28:958973.
9. Rutkowski B. Lipid disturbances in chronic renal failure patomechanisms and treatment. Roczniki Akademii Medycznej w Białymstoku 2004; 49:139-144
10. Liu, J. Lipid abnormalities associated with end-stage renal disease. Seminars in Dialysis 2006;19(1):32-40.
11. Amin K, Javed M, Muhammad Abid M, Iqbal M, Abdul Qayyum A. Pattern of dyslipidemia in patients with CRF. Professional Med J 2006;13(1):79-84.
12. Fried L, Orchard T, Kasiske B. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001;59:260269.
13. Chien K, Lin H, Hsu H, Chen M. Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterol. Lipids Health Dis 2011;10:215(28):1-9
14. Nitin S, Nagane N, Ganu J. Lipid profile and serum paraoxonase1 activity in CRF patients pre and posthemodialysis. Al Ame en J Med Sci 2011;4(1):61- 68.
15. Norris K, Vaziri N. Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. Nephrol Dial Transplant 2012:28(2):313-320
16. Brites F, Karina M, Paula Ischoff M, Hugo Beresan H, Elbert Alicia, Wikinski R. Chronic renal failure in diabetic patients increases lipid risk factors for atherosclerosis. Diabetes Res Clin Pract 2007;75:35 41.
17. Şengül E, Binnetoğlu E, Yılmaz A. Kronik böbrek hastalarında serum ürik asit düzeyi ile glikoz, HbA1c, lipit profili, vücut kitle indeksi ve kan basıncı arasındaki ilişki. DEÜ Tıp Fakültesi Dergisi 2012;25(3):163168.
18. Attman P, Samuelsson O, Johansson A, Moberly P, Alaupovıc P. Dialysis modalities and dyslipidemia. Kidney Int 2003;84:S110S112.
19. Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei BL, van Tits BL, Kolsters G, et al. The effect of the initiation of renal replacement therapy on lipid profile and oxidative stress during the first 6 months of treatment. Clin Chim Acta 2005;361:112118.
20. Teramoto T, Watanabe H, Ito K, OmataY, Furukawa T, Shimoda K, et al. Significant effects of diacylglycerol on body fat and lipid metabolism in patients on hemodialysis. Clin Nutr 2004;23:11221126.
21. Suresh D, Silvia W, Agarwa, R. Lipid peroxidation and total antioxidant capacity in patients with chronic renal failure. Asian Journal of Biochemistry 2008;(5):315- 319.
22. Menevşe E, Sivrikaya A, Karagözözlü E, Tiftik A,Türk S. Study of elements, antioxidants and lipid peroxidation in hemodialysis patients. Turk J Med Sci 2006;36(5):279-284.
23. Kushiya F, Wada H, Sakakura M, Yoshitaka Mori Y, Gabazza E, Nihikawa M, et al. Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. Clin Appl Thrombosis/Hemostasis 2003;9(3):203-210.
24. Hamamcıoğlu K, Vural O. Statins for the treatment of multiple sclerosis. J Neurol Sci 2005;22(2):221-230.
25. Nain A, Morad M, Mortazavi M, Harandi A, Hadizadeh M, Shirani F, et al. Effects of oral l-carnitine supplementation of lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: A randomized, double-blinded, placebo-controlled trial. J Nutr Metab 2012;12:1-6.
26. Duranay M, Akay H, Meriç F ̧ Enes M, Tekeli N, Yücel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 2006;21:32113214.
27. Calvani M, Benatti P, Mancinelli A, Diddio S, Giordano V, Koverech A, et al. Carnitine replacement in end-stage renal disease and hemodialysis. Ann NY Acad Sci 2004;1033:5266.
28. Özener Ç, İIçöI B, Budak Y, Emerk K, Akoğlu E. Hemodiyaliz Hastalarında Plazma Serbest Karnitin Düzeyleri ve Karnitin Tedavisinin Lipid Profiline Etkisi, Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, 1995;(1):33-36
29. National Kidney Foundation (NKF) K/DOQI. Clinical practice guidelines for cardiovascular disease in dialysis patients. 2005;45:4, Suppl 3. http://www.kidney.org
30. Çalışkan Y, Yıldız A. Kronik böbrek hastalığında beslenme desteği, İç Hastalıkları Dergisi 2010;17:247- 256.
31. National Kidney Foundation (NKF) K/DOQI. Clinical practice guidelines for managing dyslipidemias in chronic kidney disease. 2003;41:4, Suppl 3. http://www. kidney.org
32. Gülcen B, Karaca Ö, Kuş MA, Dilara Kaman D, Ögetürk M, Kuş, İ. Omega3 yağ asitlerinin böbrek antioksidan savunma sistemi üzerindeki etkisi: Deneysel bir çalışma. Balıkesir Saglik Bil Derg 2012;1:2:70-75.
33. Ertek S, Karatan O. Böbrek hastalıklarının tedavisinde omega3 yağ asitlerinin yeri. Ankara Üniversitesi Tıp Fakültesi Mecmuası 2004;57(4):249-255.
34. Özkan Y, Koca SS. Hiperlipidemi tedavisinde omega-3 yağ asitinin (balık yağı) etkinliği. Fırat Tıp Dergisi 2006;11(1): 40-44.
35. Daud Z, Tubie B, Adams J, Quainton J, Osia R, Tubie S, et al. Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients. Vasc Health Risk Manag 2012;8:187195.
36. Miller E, Juraschek S, Appel L, Madala M, Anderson C, Bleys J, et al. The effect of n3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. Am J Clin Nutr 2009;89:19371945.
37. Mekki K, Bekada N, Boukaddoum A, Krouf D, Kaddous A, Bouchenak M. N-3 fatty acid supplementation reduces hypertriacylglycerolaemia and improves lipid peroxidation and inflammation in patients with chronic renal failure. Proceedings of the Nutrition Society 2008; 67:185 doi:10.1017/S0029665108008173
38. Boukaddoum A, Taleb W, Bouzidi N, Mekk, K, Kaddous A, Bouchenak M. Omega-3 supplementation associated with nutritional advice improves oxidative stress and inflammation markers in chronic renal failure patients. Proc Nutr Soc 2010;69:248 doi:10.1017/ S0029665110000376
39. Kris-Etherton PM, William P, Harris S, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747- 2757.
40. Uslu S, Çolak Ö, Demir A, Berber A, Özdemir G, Alataş Ö. Hemodiyaliz hastalarinda kardiak belirteçler ve iz elementler. Türk Klinik Biyokimya Dergisi 2005;3(3):85-93.
41. Günal S, Üstündağ B, Günal AÇ. KBYli hastalarda, farklı hipertansif tedavi yöntemlerinin endotelyal fonksiyonlara olan etkisinin biyokimyasal parametrelerle incelenmesi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 2010;19(1):17-22.
42. Akay H, Yılmaz F, Duranay M, Altay M, Çelik N. Kronik periton diyalizi ve hemodiyaliz hastalarında homosistein ve CRP. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 2007;16(2):73-76.